Skip to main content
. 2023 Feb 13;15(2):622. doi: 10.3390/pharmaceutics15020622

Table 3.

Clinically approved mAbs.

Target mAb Type
anti-CD20 antibody rituximab lymphoma, chronic lymphocytic leukemia
anti-EGFR antibody cetuximab head and neck cancer and colorectal cancer
anti-HER2 antibody trastuzumab HER2-positive metastatic breast cancer

Abbreviations: EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor-2.